# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001171843-19-002459
Filing Date
2019-04-17
Accepted
2019-04-17 10:35:15
Documents
5
Effectiveness Date
2019-04-17

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE ADDITIONAL MATERIALS | defa14a_041719.htm | DEFA14A | 13017
2 | GRAPHIC | card_1.jpg | GRAPHIC | 419728
3 | GRAPHIC | card_2.jpg | GRAPHIC | 612191
4 | GRAPHIC | card_3.jpg | GRAPHIC | 337304
5 | GRAPHIC | card_4.jpg | GRAPHIC | 186131
| Complete submission text file | 0001171843-19-002459.txt |  | 2156090

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 19752428
SIC: 2836 Biological Products, (No Diagnostic Substances)